Literature DB >> 21069517

An unusual case of allopurinol hypersensitivity syndrome potentiated by intravitreal bevacizumab.

Biswa Mohan Padhy, Yogendra Kumar Gupta, Saravana Perumal Shanmugam, Naina Ranjit Bamrolia.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21069517     DOI: 10.1007/s00228-010-0945-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  6 in total

1.  The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.

Authors:  A E Fung; P J Rosenfeld; E Reichel
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638

2.  Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization.

Authors:  Ioannis D Ladas; Marilita M Moschos; Thanos D Papakostas; Athanasios I Kotsolis; Ilias Georgalas; Michail Apostolopoulos
Journal:  Clin Ophthalmol       Date:  2009-06-02

3.  Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.

Authors:  Nicola Dalbeth; Lisa Stamp
Journal:  Semin Dial       Date:  2007 Sep-Oct       Impact factor: 3.455

4.  Papulopustular eruption after intravitreal bevacizumab (Avastin).

Authors:  Luis Amselem; Manuel Diaz-Llopis; Salvador Garcia-Delpech; Javier Montero; Paula Palomares; Enrique Cervera
Journal:  Acta Ophthalmol       Date:  2008-06-18       Impact factor: 3.761

5.  Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?

Authors:  H Y Lee; J T Ariyasinghe; T Thirumoorthy
Journal:  Singapore Med J       Date:  2008-05       Impact factor: 1.858

Review 6.  Adverse drug reactions in clinical practice: a causality assessment of a case of drug-induced pancreatitis.

Authors:  Andreea Farcas; Marius Bojita
Journal:  J Gastrointestin Liver Dis       Date:  2009-09       Impact factor: 2.008

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.